These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 21904088)

  • 1. Medication adherence and symptom reduction in adults treated with mixed amphetamine salts in a randomized crossover study.
    Adler LA; Lynch LR; Shaw DM; Wallace SP; Ciranni MA; Briggie AM; Kulaga A; O'Donnell KE; Faraone SV
    Postgrad Med; 2011 Sep; 123(5):71-9. PubMed ID: 21904088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
    Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
    Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
    Spencer TJ; Abikoff HB; Connor DF; Biederman J; Pliszka SR; Boellner S; Read SC; Pratt R
    Clin Ther; 2006 Mar; 28(3):402-18. PubMed ID: 16750455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical effects of lisdexamfetamine and mixed amphetamine salts immediate release in adult ADHD: results of a crossover design clinical trial.
    Adler LA; Alperin S; Leon T; Faraone S
    Postgrad Med; 2014 Sep; 126(5):17-24. PubMed ID: 25295646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study.
    Weisler RH; Greenbaum M; Arnold V; Yu M; Yan B; Jaffee M; Robertson B
    CNS Drugs; 2017 Aug; 31(8):685-697. PubMed ID: 28712074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study.
    Biederman J; Boellner SW; Childress A; Lopez FA; Krishnan S; Zhang Y
    Biol Psychiatry; 2007 Nov; 62(9):970-6. PubMed ID: 17631866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A community assessment, open-label study of the safety, tolerability, and effectiveness of mixed amphetamine salts extended release in school-age children with ADHD.
    Ambrosini PJ; Sallee FR; Lopez FA; Shi L; Michaels MA;
    Curr Med Res Opin; 2006 Feb; 22(2):427-40. PubMed ID: 16466615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind study of SHP465 mixed amphetamine salts extended-release in adults with ADHD using a simulated adult workplace design.
    Wigal T; Brams M; Frick G; Yan B; Madhoo M
    Postgrad Med; 2018 Jun; 130(5):481-493. PubMed ID: 29809075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stimulant dosing for children with ADHD: a medical claims analysis.
    Olfson M; Marcus S; Wan G
    J Am Acad Child Adolesc Psychiatry; 2009 Jan; 48(1):51-9. PubMed ID: 19218896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase 3, Randomized Double-Blind Study of the Efficacy and Safety of Low-Dose SHP465 Mixed Amphetamine Salts Extended-Release in Children with Attention-Deficit/Hyperactivity Disorder.
    Mattingly G; Arnold V; Yan B; Yu M; Robertson B
    J Child Adolesc Psychopharmacol; 2020 Nov; 30(9):549-557. PubMed ID: 33185468
    [No Abstract]   [Full Text] [Related]  

  • 12. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, 3-way crossover, analog classroom study of SHP465 mixed amphetamine salts extended-release in adolescents with ADHD.
    Wigal S; Lopez F; Frick G; Yan B; Robertson B; Madhoo M
    Postgrad Med; 2019 Apr; 131(3):212-224. PubMed ID: 30681017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simulated driving changes in young adults with ADHD receiving mixed amphetamine salts extended release and atomoxetine.
    Kay GG; Michaels MA; Pakull B
    J Atten Disord; 2009 Jan; 12(4):316-29. PubMed ID: 18815438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of SHP465 mixed amphetamine salts in adults with ADHD in a simulated adult workplace environment.
    Wigal T; Childress A; Frick G; Yan B; Wigal S; Madhoo M
    Postgrad Med; 2018 Jan; 130(1):111-121. PubMed ID: 29087231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD.
    McGough JJ; Biederman J; Wigal SB; Lopez FA; McCracken JT; Spencer T; Zhang Y; Tulloch SJ
    J Am Acad Child Adolesc Psychiatry; 2005 Jun; 44(6):530-8. PubMed ID: 15908835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-Hoc Analyses of the Effects of Baseline Sleep Quality on SHP465 Mixed Amphetamine Salts Extended-Release Treatment Response in Adults with Attention-Deficit/Hyperactivity Disorder.
    Surman CBH; Robertson B; Chen J; Cortese S
    CNS Drugs; 2019 Jul; 33(7):695-706. PubMed ID: 31228031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial.
    Weisler RH; Biederman J; Spencer TJ; Wilens TE; Faraone SV; Chrisman AK; Read SC; Tulloch SJ
    CNS Spectr; 2006 Aug; 11(8):625-39. PubMed ID: 16871129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study.
    Spencer TJ; Adler LA; Weisler RH; Youcha SH
    J Clin Psychiatry; 2008 Sep; 69(9):1437-48. PubMed ID: 19012813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.